ArticlePloS one2017
Altered Epithelial Gene Expression in Peripheral Airways of Severe Asthma.
Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 2 syntheses or guidelines pooled it, 59 citations in OpenAlex.
- Immune and inflammatory mechanisms in asthma: insights into epigenetic modifications.Frontiers in immunology · 2025Pooled it
- Increasing reproducibility, robustness, and generalizability of biomarker selection from meta-analysis using Bayesian methodology.PLoS computational biology · 2022Pooled it
- Airway remodelling rather than cellular infiltration characterizes both type2 cytokine biomarker-high and -low severe asthma.Allergy · 2022Trial
- Article
- Integrated transcriptomic analysis identifies tsRNA-mRNA regulatory axis in asthma pathogenesis.The World Allergy Organization journal · 2026Article
- Multicohort Analysis of Bronchial Epithelial Cell Expression in Healthy Subjects and Patients with Asthma Reveals Four Clinically Distinct Clusters.American journal of respiratory cell and molecular biology · 2025Article
- LINCATRA: Two-cycle method to amplify RNA for transcriptome analysis from formalin-fixed paraffin-embedded tissue.Heliyon · 2024Article
- Asthma Phenotypes in the Era of Personalized Medicine.Journal of clinical medicine · 2023Review
- MAIT cells and the microbiome.Frontiers in immunology · 2023Review
- Association Between Asthma and Reduced Androgen Receptor Expression in Airways.Journal of the Endocrine Society · 2022Article
- Identifying Bacterial Airways Infection in Stable Severe Asthma Using Oxford Nanopore Sequencing Technologies.Microbiology spectrum · 2022Article
- Steroid-induced fibroblast growth factors drive an epithelial-mesenchymal inflammatory axis in severe asthma.Science translational medicine · 2022Article
- Article
- Article
- Poly-L-arginine promotes asthma angiogenesis through induction of FGFBP1 in airway epithelial cells via activation of the mTORC1-STAT3 pathway.Cell death & disease · 2021Article
- Peripheral airways type 2 inflammation, neutrophilia and microbial dysbiosis in severe asthma.Allergy · 2021Article
- Severe Adult Asthmas: Integrating Clinical Features, Biology, and Therapeutics to Improve Outcomes.American journal of respiratory and critical care medicine · 2021Review
- Wnt Signaling Is Deranged in Asthmatic Bronchial Epithelium and Fibroblasts.Frontiers in cell and developmental biology · 2021Article
- Review
- Expression of SARS-CoV-2 entry receptors in the respiratory tract of healthy individuals, smokers and asthmatics.Respiratory research · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
Management of severe asthma remains a challenge despite treatment with glucocorticosteroid therapy. The majority of studies investigating disease mechanisms in treatment-resistant severe asthma have previously focused on the large central airways, with very few utilizing transcriptomic approaches. The small peripheral airways, which comprise the majority of the airway surface area, remain an unexplored area in severe asthma and were targeted for global epithelial gene expression profiling in this study. Differences between central and peripheral airways were evaluated using transcriptomic analysis (Affymetrix HG U133 plus 2.0 GeneChips) of epithelial brushings obtained from severe asthma patients (N = 17) and healthy volunteers (N = 23). Results were validated in an independent cohort (N = 10) by real-time quantitative PCR. The IL-13 disease signature that is associated with an asthmatic phenotype was upregulated in severe asthmatics compared to healthy controls but was predominantly evident within the peripheral airways, as were genes related to mast cell presence. The gene expression response associated with glucocorticosteroid therapy (i.e. FKBP5) was also upregulated in severe asthmatics compared to healthy controls but, in contrast, was more pronounced in central airways. Moreover, an altered epithelial repair response (e.g. FGFBP1) was evident across both airway sites reflecting a significant aspect of disease in severe asthma unadressed by current therapies. A transcriptomic approach to understand epithelial activation in severe asthma has thus highlighted the need for better-targeted therapy to the peripheral airways in severe asthma, where the IL-13 disease signature persists despite treatment with currently available therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.